Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population

Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population

AZD7442 (150 mg of tixagevimab plus 150 mg of cilgavimab) has been approved for the preexposure prophylaxis of COVID-19 and for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of severe COVID-19. Thus, the aim of the present...

Full description

Saved in:

Bibliographic Details
Main Authors:	Constant Gillot, Jean-Louis Bayart, Vincent Maloteau, Jean-Michel Dogné, Jonathan Douxfils, Julien Favresse
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Case Reports in Infectious Diseases
Online Access:	http://dx.doi.org/10.1155/2024/9163490
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 omicron subvariant during pregnancy - A case series study
by: Marie Didembourg, et al.
Published: (2025-01-01)

Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.
by: Giovanni Manfredi Assanto ,, et al.
Published: (2023-10-01)

Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
by: Hovav Azuly, et al.
Published: (2024-12-01)

Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial
by: Ernest Choy, et al.
Published: (2025-01-01)

The XIAP inhibitor AZD5582 improves the treatment effect of microwave ablation on hepatocellular carcinoma
by: Wenhui Wang, et al.
Published: (2025-01-01)

Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination
by: Francesca Dapporto, et al.
Published: (2022-01-01)

AZD8055 Is More Effective Than Rapamycin in Inhibiting Proliferation and Promoting Mitochondrial Clearance in Erythroid Differentiation
by: Qian Liu, et al.
Published: (2024-01-01)

TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC
by: Xiao-Mei Tang, et al.
Published: (2025-02-01)

Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants
by: Léa Dépéry, et al.
Published: (2025-01-01)

Uncovering Gender and Age Neutrality in CT Values for E and RdRp Gene Amplification in SARS-CoV-2
by: Ibrahim A. Naqid, et al.
Published: (2023-12-01)

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)

Asymptotic analysis of mathematical model describing a new treatment of breast cancer using AZD9496 and palbociclib
by: Ophir Nave, et al.
Published: (2025-01-01)

Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay
by: Danielle W. Ali, et al.
Published: (2024-12-01)

Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants
by: Jaehyeon Hwang, et al.
Published: (2025-01-01)

Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus nephritis driven by the results of clinical trialsResearch in context
by: Yue Zhao, et al.
Published: (2025-02-01)

Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
by: Vipan Kumar Sohpal
Published: (2020-09-01)

Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies.
by: Peter R McIlroy, et al.
Published: (2025-01-01)

Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.
by: Christopher T Edwards, et al.
Published: (2025-01-01)

Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far
by: Radi Taha Alsafi
Published: (2022-01-01)

MODES OF SARS-COV-2 TRANSMISSION
by: Nilesh D. Patel, et al.
Published: (2021-07-01)

Airborne Transmission of the SARS-CoV-2 Delta Variant and the SARS-CoV-2 Omicron Variant
by: Byung Uk Lee
Published: (2021-12-01)

Extensive Longitudinal Transverse Myelitis Temporally Related to the Use of AZD1222, AstraZeneca COVID-19 Vaccine: Cerebrospinal Fluid Analysis and Recent Data Review
by: Paulo Diniz da Gama, et al.
Published: (2022-01-01)

Antiviral activity of natural compounds extracted from Mediterranean medicinal plants against SARS-CoV-2
by: Stephanie Ghio, et al.
Published: (2024-08-01)

Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers
by: Cucunawangsih Cucunawangsih, et al.
Published: (2021-01-01)

Enfisema subcutáneo y neumomediastino en un paciente con infección por SARS-COV-2: SEPIM-SARS-COV-2
by: Jesica Naanous-Rayek, et al.
Published: (2024-01-01)

Genomic and epidemiological analysis of SARS-CoV-2 variants isolated in Guinea: a routine sequencing implementation
by: Aminata Mbaye, et al.
Published: (2025-01-01)

A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
by: Zhe Chen, et al.
Published: (2025-01-01)

Myocardial Damage in SARS-CoV-2 Infection
by: Elizabeth Sellén Sanchén, et al.
Published: (2020-11-01)

Clinical Traits of SARS-CoV-2 Infection
by: O. Yu. Zolnikova, et al.
Published: (2020-12-01)

Bat reservoirs related to SARS-CoV-2
by: Sebastian Iglesias
Published: (2020-09-01)

Une diffusion de plus en plus large
by: Esther Cloutier
Published: (2004-05-01)

SARS-CoV-2 drug resistance and therapeutic approaches
by: Sania Batool, et al.
Published: (2025-01-01)

On the space of SARS-CoV-2 genetic sequence variants
by: A. Yu. Palyanov, et al.
Published: (2023-12-01)

Ebola Virus and SARS-CoV-2: Similarities and Differences
by: Robert C. SIZEMORE, et al.
Published: (2020-07-01)

Gross Hematuria following SARS-CoV-2 Vaccination
by: Maryam Sattari, et al.
Published: (2023-01-01)

Human infection studies and the SARS-CoV-2 pandemic
by: Jörg Tremmel
Published: (2022-04-01)

Recent developments in the therapeutics of SARS-CoV-2 infection
by: Priyanka Nagu, et al.
Published: (2024-12-01)

Nonhuman primate antigenic cartography of SARS-CoV-2
by: Annika Rössler, et al.
Published: (2025-01-01)

Case report: Treatable immune-mediated severe orthostatic hypotension in SARS-CoV-2 infection
by: Kenji Theiler, et al.
Published: (2025-01-01)

Seroprevalence of IgM/IgG and Neutralizing Antibodies against SARS-CoV-2 in Unvaccinated Young Adults from Mexico Who Reported Not Having Had a Previous COVID-19 Infection
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024-01-01)